Company News
04/19/2024
ivWatch prevents IV leakage events at Frimley Health
Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous …
04/17/2024
U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure
Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning. …
04/15/2024
Activation Capital Welcomes Dr. Jim Pannucci as its Vice President of Entrepreneurship
Activation Capital, an innovation ecosystem development organization, announced today that it has appointed Jim Pannucci, Ph.D., PMP as its Vice President of Entrepreneurship. As the new Vice President of Entrepreneurship, Dr. Pannucci will help Activation Capital continue to grow a deep talent base of life sciences entrepreneurs operating in the region and help empower them …
04/10/2024
Phlow kicks off drug ingredient production in Petersburg
A local pharma company and player in a regional effort to build a pharmaceutical hub in Central Virginia has started manufacturing operations. Richmond-based Phlow Corp. recently began manufacturing ingredients used in medicines at a facility at 2818 N. Normandy Drive in Petersburg, according to Robby Demeria, the company’s chief corporate affairs officer. The 19,200-square-foot facility …
04/03/2024
TearSolutions, Inc. Appoints Dr. Louis M Alpern to its Board of Directors
TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED) and other ocular surface related diseases, today announced that Louis M Alpern, MD, MPH, FACS, FICS has been appointed to the Company’s Board of Directors. “Dr. Alpern brings extensive real-world clinical experience treating patients with ocular …
04/01/2024
RIVANNA® Welcomes Craig Loomis to Drive Product Excellence
RIVANNA®, a developer of imaging-based medical solutions, names Craig Loomis as senior director of product management. With over 25 years of extensive experience in global product development and commercialization within the healthcare sector, Craig Loomis will play a vital role in advancing RIVANNA’s new product commercialization strategies. Before joining RIVANNA, Mr. Loomis held progressively responsible …
03/28/2024
ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure …
03/28/2024
AMPEL BioSolutions’ Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus. Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI. The LuGENE® lab test is now launching at …
03/27/2024
Shaping Tomorrow’s Innovators: LifeNet Health’s Educational Partnership Ignites Student Passion in Life Science
LifeNet Health, a global leader in regenerative medicine, recently collaborated with AP biology students at Landstown High School to offer hands‐on learning experiences with human tissue and cellular solutions. This initiative is part of the Life Sciences Virginia pilot program, which aims to foster interest in life science careers among students and cultivate a talent …
03/25/2024
NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13
The NIMML Institute (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for autoimmune diseases, today recognized its co-founders, Dr. Josep Bassaganya-Riera and Dr. Raquel Hontecillas, and scientific director Dr. Andrew Leber for their leadership in the discovery and development of NX-13 that enabled today’s acquisition of Landos Biopharma, Inc. …
03/21/2024
Innovation board promises $100,000 grant for rural regions
Rural Southwest and Southside Virginia are in line for a new six-figure grant for entrepreneurship, the Virginia Innovation Partnership Corporation has announced. The innovation partnership, which held its board meeting Wednesday at the New College Institute in Martinsville, gave word at a Tuesday night dinner that it will commit $100,000. That’s the latest grant in …
03/11/2024
Tagatose Becomes First Sweetener and Ingredient to Earn NutraStrong™ Prebiotic Verified Certification
Tagatose, a monosaccharide that has gained popularity for its ability to meet calorie-reduction targets without compromising taste, texture or function, is now the first sweetener to attain the NutraStrong™ Prebiotic Verified certification. Bonumose, Inc., a producer of tagatose, and ASR Group, its distributor, are proud to announce that tagatose is also the first ingredient to earn …
03/11/2024
U.S. Army funds development of a blood test for PTSD
James Grinias, Ph.D., a professor in the Department of Chemistry and Biochemistry in the College of Science & Mathematics, at Rowan University has received $356,993 in Small Business Technology Transfer funding from the U.S. Army to develop a portable system for detecting evidence of post-traumatic stress disorder (PTSD) within the blood of service members. Grinias …
03/07/2024
VCU’s new Startup Accelerator will propel university research that has market potential
After years of supporting startups that license inventions created by university researchers, Virginia Commonwealth University’s Office of the Vice President for Research and Innovation has launched its first formal Startup Accelerator program. “Our accelerator will fast-track our VCU-borne companies, giving them more personalized coaching and advisory services from our lineup of entrepreneur experts-in-residence,” said P. Srirama Rao, …
03/07/2024
With NIH grant, Springbok Analytics takes on rotator cuff injuries
Springbok Analytics, a Charlottesville medical data company that creates 3D models from X-rays and MRIs, has received a $1.7 million government grant to develop a commercially viable algorithm that can detect and diagnose shoulder injuriesThe grant, announced Tuesday, comes from the National Science Foundation’s Small Business Innovation Research grant program. It follows a $51,409 grant …
03/06/2024
Alliance for Building Better Medicine Earns NSF Engines Development Award by the U.S. National Science Foundation
The U.S. National Science Foundation has announced that the public and private sector stakeholders in the Richmond-Petersburg region, working together as the Alliance for Building Better Medicine, will receive one of the first-ever NSF Regional Innovation Engines (NSF Engines) Development Awards including $1M in funding. NSF Engines represent one of the single largest broad investments …
03/05/2024
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announced the pricing of its “reasonable best efforts” public offering of 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares (or pre-funded warrants in lieu thereof), Series D warrants to purchase an aggregate of up to …
03/04/2024
VIPC’s Virginia Venture Partners Invests in The Tiny Cargo Company to Scale and Protect Novel Drug Delivery Platform
The Virginia Innovation Partnership Corporation (VIPC) today announced that Virginia Venture Partners (VVP), its equity investment program, has invested in The Tiny Cargo Company. The Roanoke, Va.-based spinout from Virginia Tech is developing a patent-pending drug delivery platform that utilizes milk-derived exosomes and is positioned to be the B2B global leader in supply and application …
03/01/2024
ivWatch Partners with National Infusion Center Association (NICA)
ivWatch, LLC, the IV safety company, today announced that it has partnered with the National Infusion Center Association (NICA), an independent, nonprofit trade association and accrediting body dedicated to representing ambulatory outpatient care settings where provider-administered biologics and specialty medications are prepared and administered. In alignment, ivWatch and NICA are partnering with an emphasis on …
02/29/2024
VCU Health leads clinical trial for new treatment to help people with bowel control problems
A research team at VCU Health is leading a clinical trial to assess a novel treatment for fecal incontinence or sudden loss of control over bowel movements. The therapy involves implanting a bioengineered sphincter derived from the patient’s native cells to help them regain control of their bowels. The implantation surgery for the clinical trial …
02/21/2024
SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub
SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023. “Hundreds of organizations have been selected to join each network. …
02/21/2024
ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071, an investigational new drug based on ReAlta’s novel EPICC peptide …
02/12/2024
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 3,875,000 shares of its common stock at an offering price of $2.00 per share, for gross proceeds of $7.75 million, before deducting underwriting discounts and offering expenses. All of the shares of …
02/08/2024
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan diseases, today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome. This new product combines …